Literature DB >> 15942481

Dobutamine myocardial scintigraphy for the prediction of cardiac events after heart transplantation.

Marcus Hacker1, Andreas Tausig, Bernd Romüller, Xaver Hoyer, Volker Klauss, Ulrich Stempfle, Bruno Reichart, Klaus Hahn, Reinhold Tiling.   

Abstract

BACKGROUND: The long-term outcome after heart transplantation (HTx) is essentially influenced by the occurrence and extent of cardiac allograft vasculopathy (CAV). Single photon emission computed tomography-myocardial perfusion imaging (SPECT-MPI) has been shown to be a useful and cost-effective non-invasive method in patients with known or suspected coronary artery disease, but its role in detecting CAV remains unclear. AIM: To evaluate the accuracy and predictive value of dobutamine MPI in patients after HTx during a 12-month follow-up.
METHODS: Seventy-seven patients (60 males, 17 females) underwent a total of 216 dobutamine MPI examinations over a period of 5 years. Examinations were obtained an average of 89+/-42 months after orthotopic HTx according to a 1-day protocol using 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) with and without attenuation correction. For the present study, findings from 77 MPI examinations (one MPI examination per patient) were analysed visually and semiquantitatively using a 20-segment model. Summed stress scores (SSS) and summed rest scores (SRS) were calculated and receiver operating characteristic (ROC) analysis was performed to detect optimum threshold values. Patients were followed up for 12 months and cardiac events were registered.
RESULTS: Cardiac events were observed in 10 of the 77 patients. Good interobserver agreement was found for global visual and SRS-/SSS-based analysis (kappa=0.74 and 0.66, respectively). SSS was superior to SRS in the detection of cardiac events. ROC analysis showed an optimized SSS threshold value of three. For predicting a cardiac event during the 12-month follow-up, global visual and semiquantitative analysis reached sensitivities of 90% and 90%, specificities of 72% and 88%, accuracies of 74% and 87%, positive predictive values of 32% and 53% and negative predictive values of 98% and 98%, respectively. The sensitivity, specificity, accuracy and positive and negative predictive values for MPI to detect clinically relevant coronary artery stenoses (> or =50%) at conventional coronary angiography were 83%, 87%, 86%, 56% and 96%, respectively.
CONCLUSIONS: Non-invasive dobutamine MPI reliably identifies patients at risk for subsequent cardiac events in cases of CAV, with a high negative predictive value of 98% and an accuracy of 87%.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942481     DOI: 10.1097/01.mnm.0000167908.30977.fe

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

Review 1.  Transplant allograft vasculopathy: Role of multimodality imaging in surveillance and diagnosis.

Authors:  Gregory A Payne; Fadi G Hage; Deepak Acharya
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

Review 2.  Imaging in patients after cardiac transplantation and in patients with ventricular assist devices.

Authors:  Bhanu Gupta; Dany Jacob; Randall Thompson
Journal:  J Nucl Cardiol       Date:  2015-04-02       Impact factor: 5.952

3.  Diagnostic and prognostic value of myocardial perfusion gated SPECT in orthotopic heart transplant recipients.

Authors:  Alain Manrique; Mathieu Bernard; Anne Hitzel; Michael Bubenheim; Christophe Tron; Denis Agostini; Alain Cribier; Pierre Véra; Jean Paul Bessou; Michel Redonnet
Journal:  J Nucl Cardiol       Date:  2010-02-12       Impact factor: 5.952

4.  New developments for the detection and treatment of cardiac vasculopathy.

Authors:  Kevin J Clerkin; Ziad A Ali; Donna M Mancini
Journal:  Curr Opin Cardiol       Date:  2017-02-15       Impact factor: 2.161

Review 5.  Diagnosis and management of coronary allograft vasculopathy in children and adolescents.

Authors:  Nathalie Dedieu; Gerald Greil; James Wong; Matthew Fenton; Michael Burch; Tarique Hussain
Journal:  World J Transplant       Date:  2014-12-24

Review 6.  The role of non-invasive imaging modalities in cardiac allograft vasculopathy: an updated focus on current evidences.

Authors:  C Sciaccaluga; N Ghionzoli; G E Mandoli; N Sisti; F D'Ascenzi; M Focardi; S Bernazzali; G Vergaro; M Emdin; S Valente; M Cameli
Journal:  Heart Fail Rev       Date:  2021-08-12       Impact factor: 4.654

7.  Prediction of long-term (> 10 year) cardiovascular outcomes in heart transplant recipients: Value of stress technetium-99m tetrofosmin myocardial perfusion imaging.

Authors:  Jesse F Veenis; Hendrik J Boiten; Jan C van den Berge; Kadir Caliskan; Alex P W M Maat; Roelf Valkema; Alina A Constantinescu; Olivier C Manintveld; Felix Zijlstra; Ron T van Domburg; Arend F L Schinkel
Journal:  J Nucl Cardiol       Date:  2017-11-07       Impact factor: 5.952

8.  Tc-99m sestamibi single photon emission computed tomography for guiding percutaneous coronary intervention in patients with multivessel disease: a comparison with quantitative coronary angiography and fractional flow reserve.

Authors:  Stefan Förster; Johannes Rieber; Christopher Ubleis; Mayo Weiss; Peter Bartenstein; Paul Cumming; Volker Klauss; Marcus Hacker
Journal:  Int J Cardiovasc Imaging       Date:  2009-09-16       Impact factor: 2.357

9.  Clinical Utility of SPECT in the Heart Transplant Population: Analysis From a Single Large-volume Center.

Authors:  Jack Aguilar; Robert J H Miller; Yuka Otaki; Balaji Tamarappoo; Sean Hayes; John Friedman; Piotr J Slomka; Louise E J Thomson; Michelle Kittleson; Jignesh K Patel; Jon A Kobashigawa; Daniel S Berman
Journal:  Transplantation       Date:  2022-03-01       Impact factor: 5.385

10.  Inhomogeneous myocardial stress perfusion in SPECT studies predicts future allograft dysfunction in heart transplant recipients.

Authors:  Christian Wenning; Alexis Vrachimis; Angelo Dell Aquila; Alvyda Penning; Jörg Stypmann; Michael Schäfers
Journal:  EJNMMI Res       Date:  2015-10-05       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.